Table 2.
Immune responses induced 28 days after three doses of priming Abdala vaccine by study groups among participants 12 to 18 and 3–11 years of age.
| 12–18 years old |
3–11 years old |
Overall 3–18 years old |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| RBD 25 μg | RBD 50 μg | P value | RBD 25 μg | RBD 50 μg | P value | RBD 25 μg | RBD 50 μg | P value | |
| Seroconversion of anti-RBD IgG (%) | 108/112 (96·43%) | 114/116 (98·28%) | 0·65 | 116/116 (100%) | 117/118 (99·15%) | 1·00 | 224/228 (98·2%) | 455/462 (98·5%) | 0·97 |
| GMT of RBD-IgG antibodies (95% CI) | 95·96 (75·0; 122·7) | 209·39 (169·6; 258·5) | <0·01 | 165·80 (136·3; 201·7) | 255·07 (210·5; 309·0) | 0·002 | 126·74 (121·9; 131·8) | 231·3 (222·6; 240·4) | <0·01 |
| Inhibition to RBD-ACE2 binding (%) | 85/112 (75·89%) | 107/116 (92·24%) | 0·014 | 107/116 (92·24%) | 114/118 (96·61%) | 0·24 | 192/228 (84·21%) | 221/234 94·44%) | <0·01 |
| Mean ACE2 inhibition % (95% CI) | 53·80 (48·66; 58·94) | 70·24 (66·15; 74·33) | <0·01 | 64·72 (60·69; 68·76) | 75·38 (71·94; 78·82) | <0·01 | 59.36 (59.32; 59·39) | 72.96 (72.92; 73·00) | <0·01 |
| Nab to live SARS-CoV-2 (%) | 46/49 (93·9%) | 60/60 (100%) | 0·18 | 100/107 (94·3%) | 105/108 (97·2%) | 0·32 | 146/156 (93·6%) | 165/168 (98·2%) | 0·07 |
| Geometric mean of Nab titres against live SARS-CoV-2 (95% CI) | 17·94 (12·1; 26·6) | 36·96 (27·3; 49·9) | <0·01 | 18·47 (14·14; 24·13) | 36·10 (28·47; 45·78) | <0·01 | 18·30 (14.70; 22.78) | 36·41 (30.26; 43.80) | <0·01 |
RBD: receptor binding domain; μg: micrograms; CI confidence Interval; E1, 12–18 years old; E2, 3–11 years old; GMT: geometric mean titres; ACE-2: angiotensin-converting enzyme; NAb: neutralising antibodies.